Expression of ACE and ACE2 in patients with hypertensive nephrosclerosis

Kidney and Blood Pressure Research

Volumn 34, Issue 3, 2011, Pages 141-149

  Wang, Gang ^a,b   Lai, Fernand Mac Moune ^a   Kwan, Bonnie C H ^a   Lai, Ka Bik ^a   Chow, Kai Ming ^a   Li, Philip K T ^a   Szeto, Cheuk Chun ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b RENMIN HOSPITAL OF WUHAN UNIVERSITY   (China)

Author keywords

ACE2; Hypertension; Renal disease

Indexed keywords

ANGIOTENSIN CONVERTING ENZYME 2; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; MESSENGER RNA;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIASTOLIC BLOOD PRESSURE; DISEASE COURSE; DISEASE SEVERITY; FEMALE; GENE EXPRESSION; GLOMERULOSCLEROSIS; GLOMERULUS; GLOMERULUS FILTRATION RATE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; KIDNEY BIOPSY; KIDNEY FIBROSIS; KIDNEY FUNCTION; KIDNEY INJURY; KIDNEY PARENCHYMA; MALE; NEPHROSCLEROSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEINURIA; SYSTOLIC BLOOD PRESSURE;

AGED; BIOPSY; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION; GLOMERULAR FILTRATION RATE; HUMANS; HYPERTENSION; IMMUNOHISTOCHEMISTRY; KIDNEY; MALE; MICRODISSECTION; MIDDLE AGED; NEPHROSCLEROSIS; PEPTIDYL-DIPEPTIDASE A; RNA, MESSENGER;

EID: 79951851839     PISSN: 14204096     EISSN: 14230143     Source Type: Journal    
DOI: 10.1159/000324521     Document Type: Article

References (35)

1. USRDS: 2007 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. Bethesda, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2007.
2. ERA-EDTA: Registry 2005 Annual Report. Amsterdam, Academic Medical Centre, 2007.
3. Opie LH: Renoprotection by angiotensin-receptor blockers and ACE inhibitors in hypertension. Lancet 2001; 358: 1829-1831. (Pubitemid 34008644)
4. Navar LG: The intrarenal renin-angiotensin system in hypertension. Kidney Int 2004; 65: 1522-1532. (Pubitemid 38407000)
5. Kobori H, Nangaku M, Navar LG, Nishiyama A: The intrarenal renin-angiotensin system: from physiology to the pathobiology of hypertension and kidney disease. Pharmacol Rev 2007; 59: 251-287. (Pubitemid 47481436)
6. Bidani AK, Griffin KA: Pathophysiology of hypertensive renal damage: implications for therapy. Hypertension 2004; 44: 595-601. (Pubitemid 39435221)
7. Fakhouri F, Placier S, Ardaillou R, Dussaule JC, Chatziantoniou C: Angiotensin II activates collagen type I gene in the renal cortex and aorta of transgenic mice through interaction with endothelin and TGF-β. J Am Soc Nephrol 2001; 12: 2701-2710. (Pubitemid 33115417)
8. Dussaule JC, Tharaux PL, Boffa JJ, Fakhouri F, Ardaillou R, Chatziantoniou C: Mechanisms mediating the renal profibrotic actions of vasoactive peptides in transgenic mice. J Am Soc Nephrol 2000; 11(suppl 16):S124-S128.
9. Lai KN, Leung JC, Lai KB, To WY, Yeung VT, Lai FM: Gene expression of the renin-angiotensin system in human kidney. J Hypertens 1998; 16: 91-102. (Pubitemid 28069825)
10. Burrell LM, Johnston CI, Tikellis C, Cooper ME: ACE2, a new regulator of the renin-angiotensin system. Trends Endocrinol Metab 2004; 15: 166-169. (Pubitemid 38510496)
11. Thomas MC, Tikellis C: ACE2: an ACE up the sleeve? Curr Enzym Inhib 2005; 1: 51-63.
12. Fogo A, Weedman B, Solez K: Hypertensive nephrosclerosis; in Atlas of Renal Pathology. Nashville, The National Kidney Foundation, 1999.
13. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D: A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 461-470. (Pubitemid 29135798)
14. Chan RW, Lai FM, Li EK, Tam LS, Chow KM, Lai KB, Li PK, Szeto CC: Intrarenal cytokine gene expression in lupus nephritis. Ann Rheum Dis 2007; 66: 886-892. (Pubitemid 46999788)
15. Applied Biosystems: Guide to Performing Relative Quantitation of Gene Expression Using Real-Time Quantitative PCR. Foster City, Applied Biosystems, 2004.
16. Wang G, Lai FM, Lai KB, Chow KM, Li KT, Szeto CC: Messenger RNA expression of podocyte-associated molecules in the urinary sediment of patients with diabetic nephropathy. Nephron Clin Pract 2007; 106: c169-c179. (Pubitemid 47172277)
17. Szeto CC, Chow KM, Lai KB, Szeto CY, Chan RW, Kwan BC, Chung KY, Li PK, Lai FM: mRNA expression of target genes in the urinary sediment as a noninvasive prognostic indicator of CKD. Am J Kidney Dis 2006; 47: 578-586.
18. Mitch W: Measuring the rate of progression of renal insufficiency; in Mitch WE, Stein J, Brenner BM (eds): The Progressive Nature of Renal Disease. New York, Churchill Livingstone, 1986, pp 203-220.
19. Ichihara A, Hayashi M, Kaneshiro Y, Suzuki F, Nakagawa T, Tada Y, Koura Y, Nishiyama A, Okada H, Uddin MN, et al: Inhibition of diabetic nephropathy by a decoy peptide corresponding to the 'handle' region for nonproteolytic activation of prorenin. J Clin Invest 2004; 114: 1128-1135. (Pubitemid 39578702)
20. Tikellis C, Johnston CI, Forbes JM, Burns WC, Burrell LM, Risvanis J, Cooper ME: Characterization of renal angiotensin-converting enzyme 2 in diabetic nephropathy. Hypertension 2003; 41: 392-397. (Pubitemid 36314606)
21. Wysocki J, Ye M, Soler MJ, Gurley SB, Xiao HD, Bernstein KE, Coffman TM, Chen S, Batlle D: ACE and ACE2 activity in diabetic mice. Diabetes 2006; 55: 2132-2139. (Pubitemid 44509989)
22. Ye M, Wysocki J, Naaz P, Salabat MR, LaPointe MS, Batlle D: Increased ACE2 and decreased ACE protein in renal tubules from diabetic mice: a renoprotective combination? Hypertension 2004; 43: 1120-1125. (Pubitemid 38579924)
23. Zhong JC, Huang DY, Yang YM, Li YF, Liu GF, Song XH, Du K: Upregulation of angiotensin- converting enzyme 2 by all- trans retinoic acid in spontaneously hypertensive rats. Hypertension 2004; 44: 907-912. (Pubitemid 39577420)
24. Konoshita T, Wakahara S, Mizuno S, Motomura M, Aoyama C, Makino Y, Kawai Y, Kato N, Koni I, Miyamori I, et al: Tissue gene expression of renin-angiotensin system in human type 2 diabetic nephropathy. Diabetes Care 2006; 29: 848-852. (Pubitemid 44115305)
25. Mizuiri S, Hemmi H, Arita M, Ohashi Y, Tanaka Y, Miyagi M, Sakai K, Ishikawa Y, Shibuya K, Hase H, et al: Expression of ACE and ACE2 in individuals with diabetic kidney disease and healthy controls. Am J Kidney Dis 2008; 51: 613-623. (Pubitemid 351400834)
26. Ingelfinger JR: ACE2: a new target for prevention of diabetic nephropathy? J Am Soc Nephrol 2006; 17: 2957-2959. (Pubitemid 44707752)
27. Lely AT, Hamming I, van Goor H, Navis GJ: Renal ACE2 expression in human kidney disease. J Pathol 2004; 204: 587-593. (Pubitemid 39585958)
28. Mezzano S, Droguett A, Burgos ME, Ardiles LG, Flores CA, Aros CA, Caorsi I, Vio CP, Ruiz-Ortega M, Egido J: Renin-angiotensin system activation and interstitial inflammation in human diabetic nephropathy. Kidney Int 2003; 64(suppl 86):S64-S70. (Pubitemid 37159630)
29. Wakahara S, Konoshita T, Mizuno S, Motomura M, Aoyama C, Makino Y, Kato N, Koni I, Miyamori I: Synergistic expression of angiotensin- converting enzyme (ACE) and ACE2 in human renal tissue and confounding effects of hypertension on the ACE to ACE2 ratio. Endocrinology 2007; 148: 2453-2457. (Pubitemid 46997072)
30. Bomback AS, Klemmer PJ: The incidence and implications of aldosterone breakthrough. Nat Clin Pract Nephrol 2007; 3: 486-492. (Pubitemid 47313030)
31. Jessup JA, Gallagher PE, Averill DB, Brosnihan KB, Tallant EA, Chappell MC, Ferrario CM: Effect of angiotensin II blockade on a new congenic model of hypertension derived from transgenic Ren-2 rats. Am J Physiol Heart Circ Physiol 2006; 291:H2166-H2172.
32. Santa Cruz Biotechnology, Inc. ACE (H-170): sc-20791. Website: http://datasheets.scbt. com/sc-20791.pdf (last accessed on January 10, 2011).
33. Abcam: Angiotensin-converting enzyme 2 antibody (ab15348). Website: http://www. abcam.com/Angiotensin-Converting- Enzyme-2-antibody-ab15348.html (last accessed on January 10, 2011).
34. Hemming ML, Selkoe DJ: Amyloid β-protein is degraded by cellular angiotensin-converting enzyme (ACE) and elevated by an ACE inhibitor. J Biol Chem 2005; 280: 37644-37650. (Pubitemid 41642372)
35. Wang G, Lai FM, Lai KB, Chow KM, Kwan CH, Li KT, Szeto CC: Discrepancy between intrarenal messenger RNA and protein expression of ACE and ACE2 in human diabetic nephropathy. Am J Nephrol 2009; 29: 524-531.